Core Viewpoint - Baiaosaitu-B (02315) announced the resignation of non-independent director Zhang Haichao due to internal work adjustments, while she will continue to hold other positions within the company [1] Group 1 - The company’s board received a written resignation report from non-independent director Zhang Haichao [1] - Zhang Haichao's resignation is attributed to internal work adjustments within the company [1] - Following her resignation, Zhang Haichao will retain other roles within the company [1] Group 2 - The company will hold a staff representative meeting on December 5, 2025, to elect Li Yan as the staff representative director of the second board [1] - Li Yan's term will last from the date the company's stock is listed on the Sci-Tech Innovation Board until the end of the second board's term [1]

BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. 百奧賽圖（北京）醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2315） 獨立非執行董事 董事名單與其角色和職能 百奧賽圖（北京）醫藥科技股份有限公司董事會（「董事會」）成員載列如下： 執行董事 沈月雷博士 （董事長、首席執行官兼總經理） 倪健博士 非執行董事 魏義良先生 周可祥博士 張蕾娣女士 華風茂先生 喻長遠博士 梁曉燕女士 職工董事 李妍女士 1 董事會下設四個董事會委員會。各董事會成員在這些委員會中所擔任的職位載列 如下： | | 審計委員會 | 薪酬與考核 | 提名委員會 | 戰略發展 | | --- | --- | --- | --- | --- | | | | 委員會 | | 委員會 | | 沈月雷博士 | | | M | C | | 倪健博士 | | M | | | | 魏義良先生 | M | | | M | | 周可祥博士 | | | | M | | 張蕾娣女士 | | | | M | | 華風茂先生 | M | C | M | | | 喻長遠博士 | M | M ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. 百奧賽圖（北京）醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2315） 海外監管公告 百奥赛图（北京）医药科技股份有限公司 本公告乃百奧賽圖（北京）醫藥科技股份有限公司（「本公司」）根據香港聯合交易所 有限公司證券上市規則第13.10B條的規定刊發。茲載列本公司於上海證券交易所 網站刊發的《關於非獨立董事離任暨選舉職工代表董事的公告》，僅供參閱。 承董事會命 百奧賽圖（北京）醫藥科技股份有限公司 董事長、首席執行官兼執行董事 关于非独立董事离任暨选举职工代表董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 沈月雷 香港，2025年12月10日 於本公告日期，本公司董事會包括董事長、 ...

Investment Rating - The report initiates coverage with a "Buy" rating for the company [5][15]. Core Insights - The company is positioned as a technology-driven biopharmaceutical firm focused on innovative drug development, aiming to become a global source of new drugs through proprietary gene editing technologies [1][21]. - The company has developed the RenMice® platform for discovering fully human therapeutic monoclonal antibodies and other antibody types, establishing a strong growth trajectory and high technical barriers [1][21]. - The "Thousand Mice, Ten Thousand Antibodies" initiative enhances development efficiency and supports the company's antibody licensing business, which is expected to contribute significantly to revenue growth [3][14]. Summary by Sections 1. Business Overview - The company operates two main business lines: preclinical products and services, and antibody molecule transfer development, leveraging its proprietary gene editing technology [21][22]. - The company has established a global sales system and aims to be a leading supplier of innovative animal models for drug development [25][30]. 2. Financial Performance - Revenue is projected to grow significantly, with estimates of CNY 13.87 billion, CNY 18.09 billion, and CNY 23.06 billion for 2025, 2026, and 2027 respectively, reflecting year-on-year growth rates of 41.5%, 30.4%, and 27.4% [4][15]. - The company is expected to achieve profitability in 2024, with a net profit forecast of CNY 1.47 billion, CNY 3.35 billion, and CNY 5.27 billion for 2025, 2026, and 2027, indicating substantial growth [4][15]. 3. Market Position and Competitive Advantage - The company differentiates itself from traditional model animal companies by integrating model platforms, antibody platforms, and efficacy validation platforms, creating a comprehensive technology platform [13][21]. - The company has a significant first-mover advantage in humanized models and has established a large inventory of humanized models, enhancing its competitive edge [13][14]. 4. Growth Drivers - The company’s antibody development business is expected to maintain significant growth as more antibody molecules enter clinical development, contributing to milestone revenues [11][14]. - The company has signed numerous transfer and licensing agreements, indicating a robust pipeline and potential for future revenue generation [14][15]. 5. Operational Highlights - The company has established three major animal centers in Nantong, Beijing, and Boston, enhancing its capacity to produce high-quality animal models for global clients [30][34]. - The company’s innovative animal models are considered essential resources for drug development, with a focus on validating drug efficacy in preclinical stages [70].

Group 1 - The core point of the article is the resignation of Zhang Haichao as the executive director of Baiaosaitu-B (02315.HK) due to internal work adjustments, effective December 10, 2025 [1] - The company's employee representative assembly has elected Li Yan as the employee representative director for the second board of directors [1]

董事会进一步宣佈，张海超博士(张博士)因本公司内部工作调整辞任本公司执行董事，于2025年12月10 日生效。 董事会同时宣佈，根据公司法、公司章程等相关规定及本公司职工代表于2025年12月5日召开的职工代 表大会结果，本公司职工代表大会推选李妍女士(李女士)担任第二届董事会职工代表董事(职工董事)。 李女士的任期自本公司A股在科创板上市之日起生效，至第二届董事会任期届满之日止。 百奥赛图-B(02315)发布公告，本公司已完成A股发行。本公司A股将于2025年12月10日在上海证券交易 所科创板上市并开始买卖。 ...

董事会进一步宣佈，张海超博士(张博士)因本公司内部工作调整辞任本公司执行董事，于2025年12月10 日生效。 智通财经APP讯，百奥赛图-B(02315)发布公告，本公司已完成A股发行。本公司A股将于2025年12月10 日在上海证券交易所科创板上市并开始买卖。 董事会同时宣佈，根据公司法、公司章程等相关规定及本公司职工代表于2025年12月5日召开的职工代 表大会结果，本公司职工代表大会推选李妍女士(李女士)担任第二届董事会职工代表董事(职工董事)。 李女士的任期自本公司A股在科创板上市之日起生效，至第二届董事会任期届满之日止。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購百奧賽圖（北京）醫藥科技股份有限公司證券的邀 請或要約。 BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. 1 董事會欣然宣佈，本公司已完成A股發行。本公司A股將於2025年12月10日 在上海證券交易所科創板上市並開始買賣。有關A股發行的若干重要資料如 下： 百奧賽圖（北京）醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2315） 內幕消息 完成A股發行；及 執行董事辭任及選舉職工董事 I. 完成A股發行 本公告由百奧賽圖（北京）醫藥科技股份有限公司（「本公司」）根據香港聯合交 易所有限公司證券上市規則（「上市規則」）第13.09(2)(a)條及證券及期貨條例 （香港法例第571章）第XIVA部的內幕消息條文（定義見上市規則）而刊發。 茲提述本公司日期為2023年3月6日、2023年3月 ...

Group 1 - The Hang Seng Index fell by 0.84%, down 215 points, closing at 25,549 points, while the Hang Seng Tech Index dropped by 1.32% [1] - The trading volume in the Hong Kong stock market reached HKD 107.8 billion in the morning session [1] - Optical communication stocks surged, driven by increased demand for high-speed optical transceiver modules, with institutions predicting a significant rise in shipment volumes next year [1] Group 2 - Notable gainers included Hongteng Precision, which rose by 7.95%, and Changfei Optical Fiber, which increased by 4.57% [1] - Zhaoyan New Drug saw an increase of over 8% due to a surge in the price of experimental monkeys, with institutions indicating a potential widening supply-demand gap [1] - The stock of Excellence Education, a provider of digital solutions for higher education, rose over 16% on its second day of trading, with its market value approaching HKD 10 billion [1] Group 3 - Oil stocks collectively declined, with geopolitical events weakening support for oil prices, although institutions remain optimistic about the long-term investment value of major oil companies [1] - PetroChina fell by 3%, Sinopec by 2.21%, and CNOOC by 2.32% [1] Group 4 - The non-ferrous metals sector faced significant declines, with Jiangxi Copper down 5.96%, Luoyang Molybdenum down 6.27%, and China Aluminum down 5.34% due to market concerns over central banks' interest rate policies [2] - Silver Noble Pharmaceuticals saw a drop of over 14%, with a cumulative decline of 25% since entering the market [2] Group 5 - Ocean Park Corporation's stock fell by 9%, reaching a new low for the year, amid financial product repayment issues faced by its controlling shareholder [3]

（原标题：港股异动 | 百奥赛图-B(02315)涨超12%创新高 即将登陆A股科创板 公司千鼠万抗开始兑现） 智通财经APP获悉，百奥赛图-B(02315)涨超12%，高见35.86港元创新高。截至发稿，涨12.52%，报 35.76港元，成交额1169.62万港元。 消息面上，百奥赛图今早发布公告称，经上海证券交易所审核同意，百奥赛图(北京)医药科技股份有限 公司发行的人民币普通股股票将于2025年12月10日在上海证券交易所科创板上市。华福证券此前研报指 出，公司千鼠万抗开始兑现，抗体授权驱动业绩爆发。考虑公司业务的高成长性及高壁垒，临床前动物 及药理药效评价基本盘稳固，抗体开发业务已逐步进入业绩兑现期，叠加潜在的新药管线具有潜力，首 予"买入"评级。 ...